Journal of Biological Chemistry
Volume 284, Issue 16, 17 April 2009, Pages 10855-10867
Journal home page for Journal of Biological Chemistry

Protein Synthesis, Post-Translational Modification, and Degradation
Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells*

https://doi.org/10.1074/jbc.M804813200Get rights and content
Under a Creative Commons license
open access

Huntingtin proteolysis is implicated in Huntington disease pathogenesis, yet, the nature of huntingtin toxic fragments remains unclear. Huntingtin undergoes proteolysis by calpains and caspases within an N-terminal region between amino acids 460 and 600. We have focused on proteolytic steps producing shorter N-terminal fragments, which we term cp-1 and cp-2 (distinct from previously described cp-A/cp-B). We used HEK293 cells to express the first 511 residues of huntingtin and further define the cp-1 and cp-2 cleavage sites. Based on epitope mapping with huntingtin-specific antibodies, we found that cp-1 cleavage occurs between residues 81 and 129 of huntingtin. Affinity and size exclusion chromatography were used to further purify huntingtin cleavage products and enrich for the cp-1/cp-2 fragments. Using mass spectrometry, we found that the cp-2 fragment is generated by cleavage of huntingtin at position Arg167. This site was confirmed by deletion analysis and specific detection with a custom-generated cp-2 site neo-epitope antibody. Furthermore, alterations of this cleavage site resulted in a decrease in toxicity and an increase in aggregation of huntingtin in neuronal cells. These data suggest that cleavage of huntingtin at residue Arg167 may mediate mutant huntingtin toxicity in Huntington disease.

Cited by (0)

3

The abbreviations used are: HD, Huntington disease; Htt, huntingtin; poly(Q), polyglutamine; HEK, human embryonic kidney; N2a, Neuro-2a; NG108-15, neuroblastoma-glioma; PC12, pheochromocytoma; MS, mass spectrometry; LC, liquid chromatography; FITC, fluorescein isothiocyanate; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol.

*

This work was supported, in whole or in part, by National Institutes of Health Grants 16375 from the NINDS and NS038144-08. This work was also supported by the Huntington Disease Society of America Coalition for the Cure, High Q Foundation, Canadian Institutes of Health Research, and the HSC (Huntington Society of Canada).